I know too much about the first quarter, and I’m trying very hard to keep my mouth shut. But I just think that we will continue to see record utilization and pull through for BIVIGAM and ASCENIV as we progress throughout 2023. We wouldn’t be this optimistic about our financial guidance and increasing and tweaking the language, I mean we do take it very seriously. For those of you who are listening, I probably know most of you, and I’ve known you for years, and I like to under promise and over deliver. My team enjoys it as well. Last year was a tremendous year for us across all measures. And we want to set targets that are achievable, that we believe we can easily meet in the face of macroeconomic challenges but also that we have a high likelihood to beat.
So yes, durable utilization for ASCENIV, durable pull-through. My commercial team has promised. And sometimes I look at them and I go, “All right. Show me, prove it,” and they’re doing it. So unfortunately, I don’t make the rules. The SEC said we filed first quarter numbers on or before May 15. I think that investors and our analysts, you can anticipate continued durable utilization, continued patients on ASCENIV therapy and growing BIVIGAM utilization across the IG and immune-compromised patient landscape.
Elliot Wilbur: Got it. One more question, if I may, and hopefully, I didn’t miss this in your prepared commentary. But can you just talk a little bit about what you’re seeing in the collection center level in terms of the capacity utilization of the various centers, donor and foot traffic trends? There’s been some media about very heavy volumes at the border, at the U.S. Mexican border. I know that doesn’t directly impact your business, but just wondering if there’s any corollary there. And then more specifically, given the strong performance of ASCENIV, I know that you still have the ability to source high RSV titer plasma from your prior supplier, but maybe just talk a little bit about what you’re seeing in terms of your internal sourcing of high RSV titer plasma at your captive collection centers?
Brian Lenz: So Elliot, I’ll take the plasma center question. Yes, visibility has never been higher on our pathway to supply self-sufficiency at our centers. We received, I would say, accelerated approvals last year. All 10 centers have been opened and are operating and collecting. So we’re clearly on track to receive FDA licensure for call it the remaining 2 by the end of this year. All the centers are operating very well. Foot traffic certainly above where we were pre-pandemic and collections are certainly meaningfully exceeding our pre-pandemic levels. As it relates to collections for BIVIGAM, ASCENIV and even Nabi, for that matter, yes, we have some other third-party contracts, but our own source plasma from our own 10 centers will more than meet the demands for the revenue forecast that we’ve set over the next couple of years.
But our goal is to collect as much plasma as we possibly can. Plasma is going one way, and we feel very confident in our collection abilities and getting these centers open and approved.
Adam Grossman: And I think we messaged in one of the last quarter call or maybe it was during the financing, we’ve invested into our own laboratories here, and we’ve identified ways to potentially screen and identify the hyperimmune RSV plasma donor faster. And as we continue throughout 2023, we think that we’ll be able to shift to more of this testing in-house. And I think that, that will help us to ensure that we have as much plasma as we need to make ASCENIV and as much normal sources we can get. I think also something that our team always works on here is third-party supply contracts where we’re even working with some new collectors now potentially bolstering and augmenting our internal supply and our existing third-party contracts with some new ones.
